• Users Online: 568
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2015  |  Volume : 2  |  Issue : 3  |  Page : 93-96

Efficacy and safety of moxifloxacin injection in treatment of acute exacerbation of chronic bronchitis


1 Department of Respiratory, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China
2 Department of Respiratory, The Second Xiangya Hospital of Central South University, Changsha, China
3 Department of Respiratory, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
4 Department of Respiratory, The Second Affiliated Hospital of Nanchang University, Nanchang, China
5 Department of Respiratory, Xinqiao Hospital, The Third Military Medical University, Chongqing, China
6 Department of Respiratory, The Second Affiliated Hospital of Hebei Medical University, Shijiazhuang, China
7 Department of Respiratory, People's Hospital of Xinjiang Uygur Autonomous Regin, Urumqi, China
8 Department of Respiratory, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
9 Department of Respiratory, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Correspondence Address:
Tiantuo Zhang
Department of Respiratory, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/2225-6482.166075

Rights and Permissions

Objective: To evaluate the clinical efficacy and safety of moxifloxacin injection in the treatment of acute exacerbation of chronic bronchitis (AECB) in daily clinical practice. Patients and Methods: From May 2009 to March 2011, a total of 1026 cases with AECB were collected from 43 hospitals in eight cities. All the patients were treated with moxifloxacin (400 mg qd) intravenously. Whether to use oral or sequential therapy was decided by the physicians according to the clinical efficacies. Patient conditions such as combined uses of drugs, efficacies and adverse events were recorded and analyzed. Results: The cure rate of infection was 83.03%, and the total effective rate of moxifloxacin injection was 93.80%. The efficacies were statistically different among subgroups with different ages, complications, forced expiratory volume in 1 s (FEV 1 %), and combined uses of drugs, respectively. Multivariable logistic regression analysis showed that the advanced age (≥65 years) and severe obstructive pulmonary disease (FEV 1 <50%) were significantly correlated with the clinical efficacies. A total of 15 cases of adverse events were recorded, and the incidence rate was 1.23%. Conclusion: Moxifloxacin injection can effectively control the infection of AECB patients with fewer adverse events.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2342    
    Printed125    
    Emailed0    
    PDF Downloaded245    
    Comments [Add]    

Recommend this journal